The group's principle activities include acquiring, developing and commercializing of pharmaceutical products for the treatment of infectious diseases, particularly the prevention and treatment of hepatitis B and C. The company has three products under development including HepeX-B or HBV that will prevent re-infection with hepatitis B in liver transplant patients, XTL-6865 or HCV to prevent hepatitis C virus re-infection following a liver transplant and XTL-2125 from the HCV-SM small molecule development program which is a small molecule non-nucleoside polymerase inhibitor for the treatment of chronic hepatitis C. The group operates from United States.
